Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XYLOCAINE vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Local anesthesia for infiltration, nerve block, epidural, spinal, and topical use,Treatment of acute ventricular arrhythmias (e.g., during cardiac surgery or myocardial infarction),Off-label: treatment of status epilepticus, neuropathic pain, and tinnitus
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Primarily hepatic via CYP1A2 and CYP3A4 to active metabolites (monoethylglycinexylidide and glycinexylidide).
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Approximately 65-70% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) is 0.8-1.3 L/kg. Higher Vd in neonates (up to 2.75 L/kg) indicates extensive tissue distribution.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Intravenous: 100%; Intramuscular: 70-90%; Epidural: near 100%; Topical: variable and low due to systemic absorption, typically <10%; Oral: less than 30% due to extensive first-pass metabolism.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No adjustment required for GFR >30 m L/min; avoid in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Child-Pugh A/B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
1-2 mg/kg (max 4.5 mg/kg) local infiltration; adjust based on lean body weight.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Reduce dose by 40-50% due to decreased clearance and increased sensitivity to CNS/cardiac effects.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
None.
There is no FDA black box warning for ALPHACAINE.
Risk of local anesthetic systemic toxicity (LAST) including CNS and cardiovascular effects, especially with inadvertent intravascular injection or high doses,Use with caution in patients with hepatic impairment, severe renal impairment, or hypovolemia,May cause methemoglobinemia, especially in infants,Monitor ECG when used intravenously for arrhythmias
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to lidocaine or amide-type local anesthetics,Stokes-Adams syndrome or severe heart block (for IV antiarrhythmic use),Severe hypotension or cardiogenic shock,Do not use for spinal anesthesia if patient has bleeding disorders or infection at injection site
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No clinically significant food interactions reported.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depression with high maternal serum levels. Use only if clearly needed.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Excreted into breast milk in low amounts (M/P ratio approximately 1.0). Considered compatible with breastfeeding; monitor for signs of local anesthetic toxicity in infant.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No standard dose reduction required. Increased plasma volume and protein binding changes may reduce free drug concentration; however, toxicity may occur with standard doses due to altered clearance. Use lowest effective dose and consider patient weight.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
Use minimum effective dose to avoid systemic toxicity; maximum dose without epinephrine is 4.5 mg/kg (not to exceed 300 mg), with epinephrine (1:200,000) is 7 mg/kg (not to exceed 500 mg). Rapid absorption from highly vascular areas (e.g., intercostal blocks) increases toxicity risk. Always aspirate before injection to prevent intravascular administration. Mixing with epinephrine prolongs duration and reduces peak plasma levels. For pediatric patients, calculate dose based on weight and use reduced concentrations (0.5-1%). In patients with hepatic impairment, reduce dose due to decreased metabolism. Concurrent use with CYP1A2 inhibitors (e.g., fluvoxamine) may increase lidocaine levels.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Avoid driving or operating machinery until numbness and effects have completely worn off.,Do not eat or drink until sensation returns to prevent biting your tongue or cheek.,Report any signs of allergic reaction (rash, difficulty breathing, swelling) to your healthcare provider immediately.,If you experience dizziness, blurred vision, ringing in ears, or metallic taste, seek emergency care.,Inform your doctor about all medications you take, especially heart medications, anticoagulants, or other local anesthetics.,Numbness and lack of sensation are normal during the procedure; do not scratch or rub the numbed area.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XYLOCAINE vs ALPHACAINE, answered by our medical review team.
XYLOCAINE is a Local Anesthetic that works by Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XYLOCAINE and ALPHACAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XYLOCAINE is: 1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 m L.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XYLOCAINE and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XYLOCAINE is classified as Category C. First trimester: No increased risk of major malformations observed in human studies. Second and third trimesters: Potential for fetal bradycardia and central nervous system depress. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.